Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. by Hall, R. E. et al.
Brtsh Journal of Cancer (1998) 78(3). 360-365
C 1998 Cancer Research Campaign
Prostate-specific antigen and gross cystic disease
fluid protein-I 5 are co-expressed in androgen
receptor-positive breast tumours
RE Hall', JA Clements2, SN Birreill and WD Tilley1
'Rinders Caner Centre, Rinders University of South Australia, Hinders Medcal Centre. Bedford Park SA 5042: 2Centre for Molecular Biotechnology, School of
Life Science, Queensland University of Technology. Gardens Point Campus, PO Box 2434, Brisbane. Old 4001, Australia
Summary Androgens regulate breast cancer cell proliferation via androgen receptor (AR)-mediated mechanisms. To investigate further the
androgen-responsiveness of human breast tumours, we examined the immunohistochemical expression of the AR and two androgen-
regulated proteins, prostate-specific antigen (PSA) and gross cystic disease fluid protein-15 (GCDFP-15), in 72 primary breast tumours. AR
immunoreactvity was present in the nuclei of breast tumour cells and was correlated with oestrogen receptor (ER; P< 0.05) and
progesterone receptor (PR; P < 0.01) status. PSA and GCDFP-15 immunoreactvity was present in the cytoplasm of tumour cells but not the
adjacent stromal cells. AR-positive cells were present in 85% (61/72) of breast tumours, and 98% (43/44) of PSA-positive and 920/o (44/48) of
GCDFP-15-positive tumours were also positive for AR. Positive immunoreactvity for both PSA and GCDFP-15 in breast tumours was highly
dependent on AR status (odds ratios of 24.0 and 4.5 respectively), but unrelated to age, ER and PR status and axillary lymph node
involvement. PSA immunoreactvity was more frequently observed in moderate and well-differentiated tumours and was significantly
(P< 0.001) associated with GCDFP-15 immunoreactivity. In conclusion, PSA and GCDFP-15 immunoreactivity was dependent on the
presence of AR, but not ER or PR in primary breast tumours.
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The hormone receptor status of breast tumours is used to deter-
mine treatment strategies and to predict overaHl survival. In addi-
tion to oestrogen (ER) and progesterone (PR) receptors. the
androgen receptor (AR) is frequently expressed in hormone-
responsive tumours. Immunohistochemical studies have demon-
strated that at least 801% of primary breast cancers contain
AR-positive tumour cells (Kuenen-Boumeester et al. 1992: Isola.
1993: Hall et al. 1996). Moreover. AR is expressed in 25% of
breast tumour metastases in the absence of ER and PR (Lea et al.
1989). Recently. we reported that the AR concentration in primary
breast tumours is predictive of treatment response to medroxy-
progesterone acetate. a synthetic progestin with both progestin and
androgenic activity (Birrell et al, 1995).
Prostate-specific antigen (PSA: hKLK3) is a member of the
human kallikrein gene family (Clements. 1994) and is an
androgen-regulated serine protease secreted by the prostate (Lilja.
1985: Henttu et al. 1992). PSA is widely used as a serum marker
for the detection of early-stage prostate cancer and monitoring
disease progression (Oesterling. 1991). PSA is also expressed in
other tissues (Diamandis and Yu. 1995. 1997) including pituitary
(Clements et al. 1996). endometrium (Clements and Mukhtar.
1994) and apocrine foci in benign breast disease (Papotti et al.
1989: Howarth et al. 1997). In addition. PSA is present in amniotic
fluid (Melegos et al. 1996). breast milk and breast cyst fluid
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(Mannello et al. 1996). The reported incidence of immunoreactive
PSA in breast tumours varies from 15% to 70% (Diamandis et al.
1994: Wu et al. 1995: Ferguson et al. 1996). PSA has also been
demonstrated in ovarian (Yu et al. 1995a) and renal (Pummer et al.
1992: Clements et al. 1997) tumours. PSA secretion is stimulated
by progesterone, glucocorticoids and mineralocorticoids. in addi-
tion to androgens. but not by oestradiol. in T-47D human breast
cancer cells (Zarghami et al. 1997). The primary substrates for
PSA are semenogelin and fibronectin. a reaction that leads to
dissolution of the seminal clot (Lilja et al. 1987). In vitro studies
suggest that other substrates for PSA include parathyroid
hormone-related peptide (Iwamura et al. 1996) and insulin-like
growth factor binding protein-3 (Cohen et al. 1992). PSA also
degrades the extracellular matrix proteins. fibronectin and laminin.
and hence may facilitate prostate tumour invasiveness (Webber et
al. 1995). suggesting that PSA expression in breast tumours may
be a marker ofdisease progression. However, the presence ofPSA
in breast tumours has been associated with favourable prognostic
markers. e.g. PR-positive tumours (Yu et al. 1994). early-stage
disease. small tumour size and ER-positive tumours (Yu et al.
1995b). Furthermore. a higher concentration of PSA in cytosolic
extracts of primary breast tumours was associated with reduced
relative risks for relapse and death (Yu et al. 1997).
Gross cystic disease fluid protein-15 (GCDFP-15). also known
as secretory actin-binding protein (Schenkels et al. 1994). is
present in approximately 50% of all breast carcinomas and, like
AR and PSA. the presence of GCDFP-15 is frequently associated
with apocrine features (Haagensen Jr. 1991). GCDFP-15 is
secreted into the saliva. sweat. tears. nasal mucus. cerumen and
seminal plasma (Schenkels et al. 1994). Secreted GCDFP-15 binds
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Fxgure 1 AR, GCDFP-15 and PSA immunoreactvity in primary breast tumours. A representative breast tumour showing (A) nuclear AR immunoreactvity.
(B) cytopasmic GCDFP-15 immunoreactivy and (C) cytoplasmic PSA immunoreacty. Stromal cells were negative for AR, GCDFP-15 and PSA in all breast
tumours. (D) Another breast tumour showing focal, granular, cytopwasmic PSA immunoreactivity. (E) PSA immunoreacivity. (F) Negative staining of the same
(i.e. a third) tumour shown in (E), folowing preabsorption of the PSA antiserum with PSA protein (control). Original magnification 250x. Bar = 40gm
to fibnnogen and actin (Schenkels et al. 1994) and to CD4
domains on T lymphocytes (Autiero et al. 1995). which has led to
the suggestion that GCDFP-15 may modulate tumour invasiveness
(Autiero et al. 1995). Although women with breast cystic disease
have an increased risk of subsequently developing breast cancer
(Haagensen Jr. 1991: Haagensen et al. 1997). the presence of
GCDFP-15 in breast tumours has been associated with ER content
(Murphy et al. 1987) and a longer relapse-free sur ival (Pagani et
al. 1994).
Androgens regulate the synthesis and secretion of both PSA
(Zarghami et al. 1997) and GCDFP-15 (Myal et al. 1991) in T47D
human breast cancer cells. Therefore. in the present study we
examined both PSA and GCDFP-15 immunoreactivity in relation
to AR immunoreactivity in primary breast tumours.
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Table 1 Co-expression of AR. ER and PR in 72 primary breast tumours
AR ER
+ve -ve +ve -ve
PR + 52a 5 47t 10
-ve 9 6 5 10
ER +ve 47c 5
-ve 14 6
aX2 = 8.95. P= 0.003. 'X2 = 14.28, P< 0.001. 'X2 = 4.64 P= 0.03.
Table 2 Co-expression of AR. PSA and GCDFP-15 in 72 primary breast
tumours
AR GCDFP-15
+ve -_e +ve -Ve
PSA +ve 43a 1 38L 6
-ve 18 10 10 18
GCDFP-15 +ve 44c 4
-ve 17 7
a,X2 = 14.78 P < 0.001. bX2 = 19.75, P<0.001. -X2 = 5.36, P=0.02.
Table 3 Association between PSA and tumour histological gradea
Grade I Grade II Grade III
PSA +ve 13 18 11
-ve 2 9 14
aGrade tumours are well differentiated, Grade II are intermediate and Grade
Ill are poorly differentiated (Blom and Riardson classfication). X2 = 7.60,
P = 0.02
MATERIALS AND METHODS
Patient variables
Median age at operation date was 59 years (range 30-86). ER and
PR content. tumour histology and axillary lymph node infiltration
w'ere determined for diagnostic purposes. ER and PR content were
examined immunohistochemically (52 cases) and biochemicallv
(20 cases). Tumour grade was not determined in five cases [three
with mixed ductal carcinoma in situ (DCIS) and two cases of
medullary carcinoma]. Tumours were graded according to Bloom
and Richardson: grade I. 22%c (15/67): grade II. 40% (27/67): and
grade III. 37% (25/67). Axillary lymph node biopsies were posi-
tihe in 42% (24/57) of cases examined. with >4 nodes posithve for
tumour in 9/24 cases.
Immunohistochemistry
Archival paraffin blocks of 72 primary breast tumours w%ere
sectioned and stained with specific polyclonal antisera for AR. PSA
and GCDFP-15. The ARu402 antiserum was a generous gift from
Drs Michael J McPhaul. Carol M Wilson and Jean D Wilson
(Department ofIntemal Medicine. University ofTexas Southwestem
Medical Center. Dallas. TX. USA). he PSA antiserum wras supplied
by Dako Corporation (Carpintena. CA. USA). The GCDFP-15 anti-
serum was generouslv provided by Dr Darrow E Haagensen Jr
(Methodist Hospital. Sacramnento. CA. USA). The primary antibody
reactions were incubated at 4°C overnight the AR antiserum was
diluted 1:500inblocking solution (Hall etal. 1996): PSA. 1:1000 and
GCDFP-15. 1:5000 (Mazoujian et al. 1983). AR was detected
followinmg microwave retrieval. as reported previously (Hall et al.
1996). PSA was detected in breast tumours following trypsin diaes-
tion: 0.1% w/v trypsin (Difco Laboratories. Detroit. MI. USA) and
0.1%7c CaCl, in Tris-buffered saline (0.005 MtTris-HCl. 0.145 m NaCI.
pH 7.6). at 37°C for 30mn. Vectastain ABC kit (Vector Labs.
Burlingame. CA. USA) and secondary anti-rabbit antibody (Vector
Labs) were used routinely. Positive immunoreactivity was detected
with the chromogen 3'3'-diaminobenzidine tetrahydrochloride
(DAB: Sigma. St Louis. MO. USA) and negative cells were counter-
stained with weak Lillie Mayer's haematoxylin. Prostate tissues were
used as AR- and PSA-positive controls. Normal rabbit immunoolob-
ulin (Dako) was used as the negative primary antibody control. The
specificity of PSA immunoreactivity in breast tumours was demon-
strated by preabsorption (overnight at 4°C) of the antiserum with a
30-fold excess of purified PSA protein (Chemicon. Temecula. CA.
USA). ARP PSA and GCDFP-15 immunoreactivity was quantified
using video image analysis (VIA) (Hall et al. 1996). The percentage
of immunopositive cells and the mean integrated optical density
(MIOD). which measures the concentrationofpositive staining. were
recorded.
Statistical analysis
Relationships between AR. ER. PR. PSA. GCDFP-15. age. tumour
grade and nodal status were analysed using chi-squared tests and
logistic regression analysis.
RESULTS
AR, PSA and GCDFP-15 immunohistochemistry
AR immunoreactivity was localized in tumour cell nuclei and was
heterogeneous. with both positively and negatively stained cells
evident within breast tumours (Figure IA). GCDFP-15 immuno-
reactivity was found in the cytoplasm of tumour cells and was
heterogeneous. with focal staining in some tumours. whereas other
tumours contained a high percentage of positively stained tumour
cells (Figure 1B). Immunoreactive PSA was also localized in the
cytoplasm oftumour cells (Figure IC) and was present extracellu-
larly in ductal luminae. Only a few breast tumours showed wide-
spread staining for PSA (Figure IC). whereas the majority of
PSA-positive tumours showed focal PSA immunoreactivity
(Figure ID and E). The specificity of stainin, for PSA in breast
tumours was demonstratedby preabsorption ofthe polyclonal anti-
serum w-ith PSA protein (Figoure 1E and F).
Relationships between tumour variables
The highest incidence of immunoreactivity obser ed for the
different variables examined (i.e. ER. PR. AR. PSA and GCDFP-
15) was 85% (61/72) for the AR (Figure 2). AR immunoreactivitv
was significantly associated with the presence of both ER
(P < 0.05) and PR (P < 0.01) in primary breast tumours (Table 1).
ER and PR positivitv were also significantly associated (P <
0.001). The presence of AR in breast tumours was significantly
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Figure 2 The percentage of primary breast tumours (n = 72) with positve
immunoreactvity for ER. PR. AR. PSA and GCDFP-1 5 respectively
Table 4 Relationships between PSA or GCDFP-15 and ER and PR status
in 72 primary breast tumours
ER PR
+ve -ve +ve -ve
PSA +ve 343 10 36 8
-ve 18 10 21 7
GCDFP-15 +ve 35c 13 37: 11
-ve 17 7 20 4
ay;= 1.44. P= 0.23. >,2 =0.48. P = 0.49. 2= 0.04. P = 0.85. IX2 =0.38.
P= 0.54.
Table 5 Logistic regression analysis of tumour variables with PSA and
GCDFP-15
Tumour Odds ratio (95% CP) Odds ratio (95% CQ)
variable
PSA GCDFP-15
Age 1.0 (1.0-1.0) 1.0 (1.0-1.0)
AR status: 23.9 (2.8-200.6) 4.5 (1 2-17.5)
ER status 1.9 (0.7-5.4) 1.1 (0.4-3.3)
PR status 1.5 (0.5-4.7) 0.7 (0.2-2.4)
Grade I: 1.0 1.0
Grade II 0.3 (0.1-1.7) 0.5 (0.1-2.2)
GradelIl 0.1 (0.1-0.7) 0.4 (0.9-1.7)
Nodal status 0.5 (0.2-1.5) 0.8 (0.3-2.4)
aConfidence intervals (Cl) that include one indicate a non-significant effect.
tThe odds ratios for an AR-positive tumour being positive for PSA or
GCDFP-15. respectively, were significantly greater than one. cUsing Grade
as the referent category, the odds ratio for a grade Ill tumour being PSA
positive was significantly less than (one-tenth) the odds of a grade tumour
being PSA positive.
associated with both PSA (P < 0.001) and GCDFP-15 (P < 0.05)
immunostaining (Table 2. ). ith themajority ofPSA-positive (98%.
43/44) and GCDFP-15-positive (92%c. 44/48) tumours beino AR
positive. There was a significant association bettween the presence
of PSA and GCDFP-15 (P < 0.001). Aith 86% (38/44) of PSA-
positive tumours alsopositive forGCDFP-15. PSA and GCDFP-15
were co-expressed in 62%7 (38/61) of AR-positiv-e breast tumours.
with a higher proportion of lower grade (i.e. grades I and LI)
primarv breast tumours beinc PSA positive compared with grade
III tumours (Table 3: P < 0.05). No significant associations were
found between PSA and ER status. PSA and PR status. GCDFP-15
and ER status or GCDFP-15 and PR status in the breast tumours
(Table 4). AR immunoreactivity xas the only significant factor
predicting both PSA- and GCDFP-15-positive staininga in breast
tumours (Table 5). AR-positive tumours were 24 and 4.5 times
more likely to be PSA and GCDFP-15 positive respectively.
Another factor significantly associated with PSA positivity was
tumour grade: grade III tumours were nine times more likely to be
PSA negative than grade I tumours (Table 5). Age. ER and PR
status ofthe tumour and axillary lymph node involvement were not
significantly associated with PSA or GCDFP-15 immunoreactivity
in primary breast tumours (i.e. odds ratios included 1.0).
DISCUSSION
AR immunoreactivity was present in a high proportion (85%7c) of
primary breast tumours and AR was frequently co-expressed with
ER and PR. as reported in previous studies (Lea et al. 1989:
Kuenen-Boumeester et al. 1992: Isola. 1993: Hall et al. 1996).
This studv identified for the first time a hi5hlv sianificant
association between PSA and GCDFP-15 expression in breast
tumours. with PSA and GCDFP-15 being co-expressed in 62% of
AR-positive breast tumours. The expression of both PSA and
GCDFP-15 was dependent upon the presence of AR in primary
breast tumours. but was unrelated to patient age. ER and PR status
ofthe primary tumour and nodal status.
GCDFP-15 immunoreactivitv was detected in 67% (48,72) of
primary breast tumours in this study. Although previous studies
indicate that approximately 50%7c of all breast carcinomas contain
GCDFP-15 protein (Haagensen Jr. 1991). there is considerable
variation in the reported incidence of GCDFP-15. Variation
between immunohistochemical studies has also been attributed to
differences in sensitivit) between GCDFP-15 antisera (cited in
Pagani et al. 1994). While the function of PSA and GCDFP-15 in
breast tumours is not known. these proteins may interact to modu-
late tumour invasion of the extracellular matrix.
The incidence ofPSA-positive tumours in the present study (i.e.
61%7) is higher than first reported (i.e. 30%) for PSA measured
by enzvme immunoassay in breast tumour cvtosolic extracts
(Diamandis et al. 1994). The incidence of PSA-positive tumours
determined in our study. however. is similar to that (i.e. 70%)
reported by Ferguson et al (1996). u-ho used an ultrasensitixe
immunoassav with a low-er limit of detection (< 1 ng 1-1). Our
studv is also in agreement with a recent immunohistochemical
study of PSA using the same polyclonal antibody (Howarth et al.
1997). In that study 62%7c (13/21) ofinfiltrating ductal carcinomas
wxere at least faintly positive for PSA. In contrast. Wu et al (1995)
reported a 15% incidence of PSA-positive breast tumours. The
lower incidence in Wu's studxwas attributed to a lack of PSA
detection in frozen cvtosols as a result of the instabilitv of the
PSA protein.
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Other studies. including those from our laboratori (Abrahamsson
et al. 1988: Aspinall et al. 1995: Zhang et al. 1998). have demon-
strated PSA reactivity in virtually all non-malignant prostates and
early-stage prostate tumours examined. In contrast. the amounts of
PSA protein in pnmary breast tumours. i.e. the percentage of
immunopositive ceHls and the concentration of PSA. appear to be
appreciably lower. This may reflect tissue-specific differences in the
regulation of PSA in breast versus prostate. Despite earlier studies
that demonstrate significant associations between PSA positivity and
either ER (Yu et al. 1995b) orPR (Yu et al. 1994). orboth ER and PR
positivity in breast tumourcytosols (Ferguson et al. 1996). no signifi-
cantassociations were found between PSA and ER orPR status in the
present study (Table 4). Importantly. one ofthe previous studies iden-
tified thatPSApositivity was significantly associated with PR and not
with ER in subsets ofbreasttumours (viz. ER + PR +: ER-PR +) (Yu
et al. 1994). The failure to detect a direct association between PSA
and PR in our study was possibly due to the relatively small number
ofcases (72) studied. In ourstudv. PSApositivity was associated with
breast tumours oflower histological grades. Loss of PSA expression
therefore is likely to be associated with a poorer outcome. as recently
found by Yu et al (1997) Interestinglv. there is a similar reduction in
PSA immunoreactivit) in cases of prostate cancer compared with
benign prostatic hperplasia. which has more homogeneous PSA
staining and agreaterpercentage ofPSA-positive cells (Abrahamsson
et al. 1988: Aspinall et al. 1995). Therefore. in both breast and
prostate cancer. it appears that loss ofPSA protein is associated with
de-differentiation during tumour development and progression.
In a previous study. we demonstrated that the level of AR in
pnrmary breast tumours is associated with response to second-line
therapy with the synthetic progestin medroxyprogesterone acetate
(Birrell et al. 1995). indicating the potential usefulness of AR as a
prognostic marker. In the present study. we have shown that.
although AR. ER and PR are co-expressed in breast tumours. PSA
and GCDFP-15 positivitv is significantly associated with AR alone
and not determined by ER or PR status of the primary tumour. The
data from this and previous studies suggest that the expression of
PSA and GCDFP-15 may be dependent on a functional ARpathway.
This study also demonstrates that immunoreactive PSA. like
GCDFP-15 (Haagensen Jr. 1991). is strongly associated with the
presence ofAR in primary breast tumours. suggesting that both PSA
and GCDFP-15 are androgen-regulated in breast tumours in vivo.
In conclusion. although it has been suggested that PSA and
GCDFP-15 may facilitate tumour invasion. the evidence presented
in this study clearly supports their association with a well-differen-
tiated phenotype in breast cancer and. therefore. better prognosis.
ABBREVIATION
AR. androgen receptor. DAB. 3'3'-diaminobenzidine tetrahv-
drochloride: DCIS. ductal carcinoma in situ. ER. oestrogen receptor.
GCDFP-15. gross cystic disease fluid protein of mol. wt 15 kDa:
MIOD. mean integrated optical density: PR. progesterone receptor.
PSA. prostate-specific antigen: VIA. video image analysis.
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